Deals in Depth: November 2023
Executive Summary
Five $1bn+ alliances were penned in November. In the top alliance by deal value, Cellectis and AstraZeneca entered into a joint research collaboration agreement to accelerate the development of next-generation therapeutics in areas of oncology, immunology and rare diseases. The deal could be worth up to $2.4bn. AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products. A total of 25 genetic targets have been exclusively reserved for AstraZeneca, which holds an option to license exclusive global rights to develop and sell up to 10 of the targets, to be exercised before IND filing.